Projects per year
Personal profile
Biography
I am a dedicated and compassionate medical oncologist with a particular interest in genitourinary and
gastrointestinal cancers. I have five years of Consultant Medical Oncology experience, predominantly treating genitourinary and lower gastrointestinal cancers. I have a particularly strong research background, with extensive experience as an investigator in clinical trials and translational research. I have completed a Masters in Clinical Epidemiology and have submitted a PhD in translational prostate cancer. Through working at the NHMRC Clinical Trials Centre and for the ANZUP Trials Group, I have developed trial management experience in large Phase 2 and 3 trials and have established solid research connections and collaborative networks.
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
MK-5684-01A: CTU: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Zhang, A., Chapman, N., Chester, C., TAIDI, G. & Martin, L.
12/04/24 → 27/03/29
Project: Research
-
V940-005: CTU: A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with High-Risk Muscle-Invasive Urothelial Carcinoma Post-Radical Resection
Zhang, A., Chapman, N. & Chester, C.
12/03/24 → 28/02/29
Project: Research
-
OMAHA-4: CTU A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA)
Zhang, A., Martin, L., Contacos, C., Chester, C., Chapman, N. & TAIDI, G.
6/02/24 → 18/01/29
Project: Research
-
OMAHA-3: CTU A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy
Zhang, A., Contacos, C., Chapman, N., Chester, C., Martin, L. & TAIDI, G.
5/02/24 → 18/01/29
Project: Research
-
CTU: A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination with Pembrolizumab in Subjects with Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2
Zhang, A., Contacos, C., TAIDI, G., Chapman, N. & Chester, C.
11/10/23 → 18/07/28
Project: Research
Research Outputs
- 14 Article
-
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
Sweeney, C. J., Martin, A. J., Stockler, M. R., Begbie, S., Cheung, L., Chi, K. N., Chowdhury, S., Frydenberg, M., Horvath, L. G., Joshua, A. M., Lawrence, N. J., Marx, G., McCaffrey, J., McDermott, R., McJannett, M., North, S. A., Parnis, F., Parulekar, W., Pook, D., Reaume, N., & 12 others , Apr 2023, In: The Lancet Oncology. 24, 4, p. 323-334 12 p.Research output: Contribution to journal › Article › peer-review
86 Citations (Scopus) -
Modulation of plasma lipidomic profiles in metastatic castration-resistant prostate cancer by simvastatin
Mak, B., Lin, H-M., Duong, T., Mahon, K. L., Joshua, A. M., Stockler, M. R., Gurney, H., Parnis, F., Zhang, A., Scheinberg, T., Wittert, G., Butler, L. M., Sullivan, D., Hoy, A. J., Meikle, P. J. & Horvath, L. G., 30 Sept 2022, In: Cancers. 14, 19, p. 1-15 15 p., 4792.Research output: Contribution to journal › Article › peer-review
Open AccessFile6 Citations (Scopus)48 Downloads (Pure) -
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
Buteau, J. P., Martin, A. J., Emmett, L., Iravani, A., Sandhu, S., Joshua, A. M., Francis, R. J., Zhang, A. Y., Scott, A. M., Lee, S-T., Azad, A. A., McJannett, M. M., Stockler, M. R., Williams, S. G., Davis, I. D., Hofman, M. S. & TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Nov 2022, In: The Lancet Oncology. 23, 11, p. 1389-1397 9 p.Research output: Contribution to journal › Article › peer-review
121 Citations (Scopus) -
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Hofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Joshua, A. M., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., Ng, S., Francis, R. J., Gedye, C., Rutherford, N. K., Weickhardt, A., Scott, A. M., Lee, S-T., Kwan, E. M., Azad, A. A., Ramdave, S., Redfern, A. D., & 14 others , 27 Feb 2021, In: Lancet. 397, 10276, p. 797-804 8 p.Research output: Contribution to journal › Article › peer-review
677 Citations (Scopus) -
Evaluation of a mainstream model of genetic testing for men with prostate cancer
Scheinberg, T., Goodwin, A., Ip, E., Linton, A., Mak, B., Smith, D. P., Stockler, M. R., Strach, M. C., Tran, B., Young, A. L., Zhang, A. Y., Mahon, K. L. & Horvath, L. G., 1 Feb 2021, In: JCO Oncology Practice. 17, 2, p. e204-e216 14 p.Research output: Contribution to journal › Article › peer-review
34 Citations (Scopus)
Prizes
Activities
- 7 Presentation
-
An analysis of multiple biomarkers to better predict prostate cancer metastasis and death after radical prostatectomy
Alison Zhang (Speaker)
8 Feb 2018 → 10 Feb 2018Activity: Talk or presentation › Presentation
-
A prospective multi-centre Phase III validation study of AZGP1 as a biomarker in localized prostate cancer
Alison Zhang (Speaker)
13 Feb 2017 → 15 Feb 2017Activity: Talk or presentation › Presentation
-
Chemotherapy reduces time to development of radiation-induced sarcomas
Alison Zhang (Speaker)
2 Jun 2017 → 6 Jun 2017Activity: Talk or presentation › Presentation
-
Toxicity-adjusted dose of sunitinib gives low-intra-patient variation of trough levels: A longitudinal study in metastatic renal cell cancer
Alison Zhang (Speaker)
30 May 2014 → 3 Jun 2014Activity: Talk or presentation › Presentation
-
Metformin to preventing androgen deprivation therapy-induced insulin resistance and the metabolic syndrome
Alison Zhang (Speaker)
27 Sept 2013 → 1 Oct 2013Activity: Talk or presentation › Presentation